Approaches to Modeling
• Flexible broad-based disease models -These models incorporate the natural history of disease processes and overlay the full range of cancer control interventions.
• Multicohort modeling-This type of modeling captures a range of birth cohorts and the changing risk factor profiles, screening behavior, and treatments used by each cohort as it ages.
• Making the results of modeling efforts more transparent-This is achieved through: -Comparative modeling-Independent modeling efforts often yield disparate results that are difficult to reconcile. A comparative modeling approach explores differences between models in a systematic way. In "base case" collaborations, a set of common population inputs is used across all models (e.g., dissemination patterns of screening and treatment, mortality from noncancer causes), and 
Working with Researchers and Policymakers
The CISNET infrastructure serves as a tool to inform evidence-based policy decisions, cancer control planning, and research priority setting. Examples include:
• Sample graphs: Estimated joint distribution of the reduction in the rate of death from breast cancer among U.S. women 30-79 years of age attributed to adjuvant treatment and to screening mammography (Berry et al., 2005) .
The usage patterns then were coupled with seven independent modelers' syntheses of all available information on the benefits of these advances. Although the benefits of adjuvant therapy were more settled, controversy regarding the benefits of mammography screening persisted due to uneven results and continuing criticism of the controlled trials on which the mortality benefits had been based. The authors make the case that each factor accounted for onehalf of the historic 24 percent decrease in mortality that was observed between 1990 and 2000. Typically, results based on observational data are validated using controlled trials. However, in this case, observational data (combined in a novel way using seven different models) helped to confirm mammography benefits when controlled trial results alone could not settle the debate.
• (continued from previous page) The results from this model varied significantly from the two other models, which were calibrated to U.S. PSA screening patterns and prostate cancer incidence data. With the original Rotterdam ERSPC data, the MISCAN model estimated that the mean lead time was 7.9 years, and the overdiagnosis frequency was 66 percent of screen-detected cancers. When this model was calibrated to U.S. SEER data, the mean lead time was 6.9 years, and the overdiagnosis frequency was 42 percent. These latter estimates were much closer to the estimates produced by the FHCRC and University of Michigan models, which estimated mean lead times ranging from 5.4-6.9 years, and overdiagnosis frequencies ranging from 23-42 percent. This led the authors to conclude that both the definitions and populations used to estimate lead time and overdiagnosis can have a significant effect on study results and should be specified clearly prior to conducting research. 
Selected Publications

